Pfizer, Biohaven

Pfizer shells out nearly $60M to resolve Nurtec kickback claims inherited in Biohaven buyout
Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments intended to boost prescriptions. | Pfizer—which purchased Biohaven for $11.6 billion in 2022—is committing more than $59.
Pfizer settles Biohaven kickback claims case for $59.7m
Biohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for preferential prescriptions.
Pfizer to pay $59.7 million over kickbacks for migraine drug
Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs by paying kickbacks so doctors would prescribe the migraine drug Nurtec ODT,
Pfizer Settles Biohaven Kickback Suit for Nearly $60M
Biohaven wielded meals at high-end restaurants and paid speaking opportunities to induce healthcare providers to prescribe its migraine therapy Nurtec ODT, according to the Department of Justice.
Pfizer to Pay $60 Million in Kickback, False Claims Settlement
Pfizer will pay $60 million to settle allegations that one of its subsidiaries incentivized healthcare providers to prescribe one of its drugs, resulting in the submission of false claims to federal healthcare programs.
Pfizer to pay nearly $60M to resolve physician kickback scheme
Pfizer, on behalf of its subsidiary Biohaven Pharmaceutical Holding Company, agreed to pay $59,746,277 to resolve allegations that prior to Pfizer's acquisition, Biohaven paid kickbacks to physicians to induce prescriptions of Biohaven’s drug Nurtec.
Pfizer to pay $60 million to settle claims that Biohaven paid kickbacks to doctors
The alleged violations occurred before Pfizer bought Biohaven and its migraine treatment three years ago for $11.6 billion.
Pfizer to pay nearly $60M over kickbacks for migraine drug once promoted by Lady Gaga
The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so that physicians would prescribe a specific migraine drug to patients.
Pfizer Settles $59.7M Medicare Kickback Case Over Biohaven Practices
Pfizer (NYSE:PFE) has agreed to pay $59.7 million to resolve allegations that Biohaven Pharmaceuticals, acquired by Pfizer in October 2022, defrauded Medicare and other healthcare programs by offering kickbacks to
Investor's Business Daily on MSN22m
Pfizer Jumps After Avoiding Proxy Fight With Activist Investor Starboard — For Now
Pfizer stock bounded off its 50-day line on Monday after avoiding a battle with activist investor Starboard Value — for now.
Pfizer Dodges Challenge to Its Board in Battle With Starboard
Pfizer Inc. got a reprieve — at least for now — in its battle with activist investor Starboard Value LP, according to people ...
What's Going On With Pfizer Stock Monday?
Pfizer Inc (NYSE:PFE) shares are trading higher Monday. Some of the optimism may be surrounding activist Starboard Value's ...
BioSpace5h
BMS, Pfizer Challenge Colorectal Cancer Standard Care With ASCO GI Readouts
Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that ...
Pfizer succeeds in late-stage trial for colorectal cancer therapy
Pfizer (PFE) colorectal cancer therapy Braftovi as part of a drug combo indicates a favorable objective response rate in a ...
Australian Associated Press3d
Pfizer CEO did not say COVID vaccines are ‘quite dangerous’ in TV interview
Mr Bourla does not say in the interview that COVID jabs are dangerous. The interview begins at the 35 seconds mark of the ...
Cherokee Phoenix2d
OKC Indian Clinic announces contribution from Pfizer to support Native women’s health
Oklahoma City Indian Clinic announced it has received a $250,000 charitable contribution from Pfizer to support programs ...
Khaleej Times on MSN3d
UAE: Pfizer to expand in GCC, vows to improve access to vaccines, 'breakthrough' treatments
Pfizer said it will 'support capacity-building initiatives, such as training healthcare professionals and advancing clinical ...